Regulus Therapeutics (NASDAQ:RGLS) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report report published on Friday, Benzinga reports. HC Wainwright currently has a $10.00 price target on the biopharmaceutical company’s stock.

RGLS has been the topic of several other reports. StockNews.com initiated coverage on Regulus Therapeutics in a research report on Tuesday, April 16th. They issued a sell rating on the stock. Oppenheimer initiated coverage on shares of Regulus Therapeutics in a research report on Friday, August 2nd. They set an outperform rating and a $7.00 price objective on the stock. Finally, Canaccord Genuity Group boosted their target price on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a buy rating in a research report on Tuesday, June 25th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Regulus Therapeutics presently has a consensus rating of Moderate Buy and an average target price of $10.80.

Regulus Therapeutics Price Performance

Shares of NASDAQ RGLS remained flat at $1.48 during trading on Friday. The stock had a trading volume of 219,342 shares, compared to its average volume of 499,284. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The company has a market capitalization of $96.89 million, a price-to-earnings ratio of -1.01 and a beta of 1.62. The company has a 50 day simple moving average of $1.94 and a 200 day simple moving average of $2.00.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.14). Equities analysts anticipate that Regulus Therapeutics will post -0.77 EPS for the current fiscal year.

Institutional Trading of Regulus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vivo Capital LLC bought a new stake in Regulus Therapeutics during the 1st quarter valued at $14,400,000. CVI Holdings LLC bought a new position in shares of Regulus Therapeutics during the first quarter valued at approximately $4,050,000. Victory Capital Management Inc. increased its holdings in Regulus Therapeutics by 16.5% during the fourth quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock valued at $348,000 after buying an additional 38,529 shares during the period. Renaissance Technologies LLC boosted its position in Regulus Therapeutics by 56.4% during the 2nd quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 42,600 shares in the last quarter. Finally, Rhumbline Advisers purchased a new position in shares of Regulus Therapeutics in the 2nd quarter valued at $136,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.